I agree with one possible exception. In my limited
Post# of 30013
If GC can uplist as a result of a major partnership announcement with a BP, I'm not going to be anticipating a whole lot of shorting and manipulation. Keep in mind, Lympro revenue is just around the corner. IMHO, if you combine imminent revenue with a major JV announcement, manipulators will want to find an easier target to attack.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)